相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antifungal use in hospitalized adults in US academic health centers
Amy L. Pakyz et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2011)
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria
Michael A. Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
M. A. Pfaller et al.
DRUG RESISTANCE UPDATES (2011)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2011)
Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida
Michael A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2011)
Molecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata
Patrick Vandeputte et al.
MYCOPATHOLOGIA (2011)
Mutational Analysis of Flucytosine Resistance in Candida glabrata
Thomas D. Edlind et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida Time for harmonization of CLSI and EUCAST broth microdilution methods
M. A. Pfaller et al.
DRUG RESISTANCE UPDATES (2010)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp.
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?
Michael A. Pfaller et al.
CURRENT FUNGAL INFECTION REPORTS (2010)
A Ser29Leu Substitution in the Cytosine Deaminase Fca1p Is Responsible for Clade-Specific Flucytosine Resistance in Candida dubliniensis
Brenda A. McManus et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniae
Martine Florent et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods
D. J. Diekema et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
Setting and revising antibacterial susceptibility breakpoints
John Turnidge et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values
J Turnidge et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome
BJ Park et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole:: Global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
Flucytosine resistance is restricted to a single genetic clade of Candida albicans
C Pujol et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Molecular mechanisms of primary resistance to flucytosine in Candida albicans
WW Hope et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Clade-specific flucytosine resistance is due to a single nucleotide change in the FURI gene of Candida albicans
AR Dodgson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States
L Ostrosky-Zeichner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
G Kahlmeter et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Comparison of caspofungin and amphotericin B for invasive candidiasis.
J Mora-Duarte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.:: Global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods
MA Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antifungal susceptibility testing: Practical aspects and current challenges
JH Rex et al.
CLINICAL MICROBIOLOGY REVIEWS (2001)
Primary resistance to flucytosine among clinical isolates of Candida spp.
F Barchiesi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
分享论文
